Director of Pharma Corporate Development at Esteve

Pharmaceutical business executive with a very strong foundation in the life sciences and substantial experience in strategic management with a special focus on R&D. Direct areas of expertise include Business Development & Licensing, Portfolio Management, Life Cycle Management, and Specialty Pharmaceutical Business Strategy.

The mission of the Pharma Corporate Development group at Esteve is to identify business opportunities for Esteve Pharma and brings together the Business Development and Licensing group, the Business Intelligence team, our Future Innovation Strategies in Health team (F.I.S.H) as well as R&D Business Strategy.

Mark joined Esteve in 2006 from the strategic consulting firm McKinsey and Company (2001-2006), where he had spent 6 years in the New York office serving Pharma and Biotech clients.  From 1998 to 2001 Mark was a Senior Scientist at Mojave Therapeutics (NY), a biotech spun out of work performed in part by Mark at Memorial Sloan Kettering Cancer Center (NY) during his post-doctoral studies at that institution (1992-1998). Mark has both a BA and a PhD in Biochemistry, from Oxford University.


Company brief: ESTEVE

  • Esteve is a leading pharmaceutical chemical group formed by more than 2,200 professionals with a clear priority: to contribute to the wellbeing of society.
  • Esteve covers the whole drug supply chain through their three main activities: pharmaceutical, chemical and generics.
  • Net sales 2015: €872m
  • International sales: 59.2%
  • R&D: €63m
  • Employees: 2,278